Hasil Pencarian - Osamu Hiranuma, MD
- Menampilkan 1 - 5 hasil dari 5
-
1
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study oleh Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Takayuki Nakano, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Diterbitkan 2022-07-01
Artikel -
2
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC oleh Kenji Morimoto, MD, PhD, Ryo Sawada, MD, Tadaaki Yamada, MD, PhD, Koichi Azuma, MD, PhD, Kentaro Ito, MD, Yasuhiro Goto, MD, PhD, Hideharu Kimura, MD, PhD, Taishi Harada, MD, Shinsuke Shiotsu, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Takayuki Takeda, MD, PhD, Osamu Hiranuma, MD, Isao Hasegawa, MD, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Diterbitkan 2022-09-01
Artikel -
3
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Tria... oleh Makoto Hibino, MD, Osamu Hiranuma, MD, Yoshizumi Takemura, MD, PhD, Yuki Katayama, MD, Yusuke Chihara, MD, PhD, Taishi Harada, MD, Kohei Fujita, MD, PhD, Toshiyuki Kita, MD, PhD, Nobuyo Tamiya, MD, PhD, Takeshi Tsuda, MD, Shinsuke Shiotsu, MD, Yukihiro Tamura, MD, PhD, Takashi Aoyama, MD, Yoichi Nakamura, MD, PhD, Masaaki Terashima, MD, PhD, Yoshie Morimoto, MD, PhD, Kazuhiro Nagata, MD, PhD, Kenichi Yoshimura, PhD, Junji Uchino, MD, PhD, Koichi Takayama, MD, PhD
Diterbitkan 2022-12-01
Artikel -
4
Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective... oleh Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Koichi Takayama, MD, PhD
Diterbitkan 2024-03-01
Artikel -
5
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study oleh Yuki Katayama, MD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Akihiro Yoshimura, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD
Diterbitkan 2023-04-01
Artikel